Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H7AC
|
|||
| Former ID |
DCL001076
|
|||
| Drug Name |
PF-03814735
|
|||
| Synonyms |
PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Discontinued in Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25F3N6O2
|
|||
| Canonical SMILES |
CC(=O)NCC(=O)N1C2CCC1C3=C2C=CC(=C3)NC4=NC=C(C(=N4)NC5CCC5)C(F)(F)F
|
|||
| InChI |
1S/C23H25F3N6O2/c1-12(33)27-11-20(34)32-18-7-8-19(32)16-9-14(5-6-15(16)18)30-22-28-10-17(23(24,25)26)21(31-22)29-13-3-2-4-13/h5-6,9-10,13,18-19H,2-4,7-8,11H2,1H3,(H,27,33)(H2,28,29,30,31)/t18-,19+/m0/s1
|
|||
| InChIKey |
RYYNGWLOYLRZLK-RBUKOAKNSA-N
|
|||
| CAS Number |
CAS 942487-16-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025628) | |||
| REF 2 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.